// App-Quantinova.ai

: Health-Related Quality of Life (HRQoL) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (Pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) in the Phase III POLARIX Study

Researchers

Presenter

  • Jonathan W. Friedberg

Principal Investigators

  • Marek Trneny

  • Franck Morschhauser

  • Gilles Salles

  • Patrick M. Reagan

  • Mark Hertzberg

  • Piotr Smolewski

  • Huilai Zhang

  • Catherine Thieblemont

  • Bei Hu

  • Gustavo Fonseca

  • Won-Seog Kim

  • Maurizio Martelli

  • Amitkumar Mehta

  • Avrita Campinha-Bacote

  • Mark Yan

  • Jamie Hirata

  • Matthew Sugidono

  • Calvin Lee

  • Jeff P. Sharman

Medical Centers

  • Willamette Valley Cancer Institute/US Oncology, Eugene, OR

  • Mayo Clinic College of Medicine, Rochester, MN

  • Wilmot Cancer Institute, University of Rochester, Rochester, NY

  • Medical University of Lodz, Lodz, Poland

  • University of Rochester School of Medicine, Rochester, NY

  • First Faculty of Medicine, Charles University, General Hospital, Prague, Czech Republic

  • Université Paris Cité, Assistance Publique - Hôpitaux de Paris, Saint-Louis Hospital, Hemato-oncology department, Paris, France

  • Hematology Department of Translational and Precision Medicine, Sapienza University, Rome, Italy

  • Florida Cancer Specialists North/Sarah Cannon Research Institute, St. Petersburg, FL

  • Tianjin Medical University Cancer Hospital, Tianjin, China

  • Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of (South)

  • Prince of Wales Hospital and University of NSW, Sydney, Australia

  • Hôpital Claude Huriez Univ. Lille, CHU Lille, ULR - GRITA - Groupe de Recherche sur les formes Injectables et les Technologies Associées and Centre Hospitalier Régional Universitaire de Lille, Lille, France

  • Memorial Sloan Kettering Cancer Center, New York, NY

  • University of Alabama at Birmingham, Birmingham, AL

  • Levine Cancer Institute, Atrium Health, Charlotte, NC

Locations

  • United States

  • Canada

  • France

  • Czech Republic

  • China

  • Republic of South Korea

  • Poland

  • Italy

  • Australia

Companies

  • Genentech, Inc.

Study Components

Therapeutic Area

  • Gastroenterology (GU)

  • Oncology (ONC)

  • Endocrine/metabolic Diseases (ME)

Disease

  • Diffuse large B-cell lymphoma

  • Constipation

  • Lymphomas

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Polatuzumab vedotin

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Vincristine

  • Doxorubicin

  • Prednisone

  • Rituximab

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved